Table 1.

Clinical, demographic, serological, and therapeutic characteristics of patients with RA and HC

	Patients with RA (n = 20)	HC (n = 20)
Demographic parameters
Female/male	19/1	20/0
Age, years (median (IQR))	58.5 (50–67)	58 (50–65)
Disease duration, years (mean ± SD),	5.3 ± 5.6
Disease activity
DAS28 (mean ± SD)	4.1 ± 1.7
TJ, n (mean ± SD)	6.16 ± 5.9
SJ, n (mean ± SD)	2.79 ± 2.7
CDAI (mean ± SD)	18.8 ± 10.7
HAQ (mean ± SD)	1.15 ± 0.8
Laboratory parameters	N (%)
RF+	15 (75)
ACPA+	15(75)
ESR, mm/h (mean ± SD)	16.5 ± 10.3
CRP, mg/dl (mean ± SD)	0.7 ± 0.73
Therapy
Concurrent csDMARDs (n (%))	20 (100)
ETA (n (%))	20 (100)

RA rheumatoid arthritis, HC healthy controls, SD standard deviation, DAS28 Disease Activity Score in 28 joints, TJ tender joints, SJ swollen joints, CDAI Clinical Disease Activity Index, HAQ Health Assessment Questionnaire, RF rheumatoid factor, ACPA anti-citrullinated peptide antibodies, ESR erythrocyte sedimentation rate, CRP C-reactive protein, csDMARDs conventional synthetic disease-modifying antirheumatic drugs